Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + tegafur + uracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of paclitaxel (a taxane), tegafur/uracil (UFT, an oral fluoropyrimidine), and leucovorin (LV, folinic acid). Paclitaxel acts as an antimitotic agent by stabilizing microtubules. Tegafur is a prodrug that converts to 5-fluorouracil (5-FU) in the body, while uracil competitively inhibits dihydropyrimidine dehydrogenase (DPD) to prevent rapid breakdown of 5-FU. Leucovorin enhances the cytotoxic effects of 5-FU by stabilizing the binding of 5-FU metabolites to thymidylate synthase, thereby inhibiting DNA synthesis in cancer cells.
- Brand names
- Orzel + paclitaxel
- Other names
- UFT/leucovorin plus paclitaxelPacl + UFT + LV
02
Targets
TS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + tegafur + uracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + tegafur + uracil + leucovorin.